Baseline tumor burden and outcomes in patients with rare cancers treated with immunotherapy (Southwest Oncology Group trial S1609)
Larger baseline tumor burden was associated with worse OS, but not PFS, and was not predictive of tumor regression after dual ICI therapy in a large cohort with rare cancer types.
Authors
- Sandip Pravin Patel (ORCID: https://orcid.org/0000-0002-8387-4840)
- Megan Othus
- Paul L. Swiecicki
- Young Kwang‐Chae
- Razelle Kurzrock
Institutions
- Northwestern University (US)
- Medical College of Wisconsin (US)
- University of Michigan (US)
- University of California San Diego (US)
- Fred Hutch Cancer Center (US)
- Cancer Research And Biostatistics (US)
- SWOG Cancer Research Network (US)
Publication Details
- Journal
- Cancer
- Published
- 2026-03-27
- DOI
- https://doi.org/10.1002/cncr.70374
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00